Freedom Nail Ankle Fusion System

K261189 · McGinley Orthopaedic Innovations · HSB · Oct 19, 2026 · Orthopedic

Device Facts

Record IDK261189
Device NameFreedom Nail Ankle Fusion System
ApplicantMcGinley Orthopaedic Innovations
Product CodeHSB · Orthopedic
Decision DateOct 19, 2026
DecisionSESE
Submission TypeTraditional
Regulation21 CFR 888.3020
Device ClassClass 2
AttributesTherapeutic

Indications for Use

The Freedom Nail Ankle Fusion System is indicated for the following: Arthrodesis of the tibiotalar joint without limiting range of motion in the subtalar joint for any of the following indications: • Diabetic neuropathic ankle joint • Severe foot/ankle deformity • Osteoarthritis • Instability and skeletal defects after tumor resection • Neuro-arthropathic deformity or Charcot deformity • Avascular necrosis of the talus • Revision of a failed joint replacement or failed ankle fusion • Distal tibial fracture and non-unions • Rheumatoid arthritis and pseudoarthrosis

Device Story

Freedom Nail Ankle Fusion System is an intramedullary nail construct for tibiotalar joint arthrodesis. System includes fusion nails, bone screws, and surgical instruments. Implanted in talus and distal tibia to achieve fusion while preserving subtalar joint range of motion. Used by orthopedic surgeons in clinical/OR settings. Provides mechanical fixation to stabilize the joint, facilitating bone healing and fusion. Benefits patients by addressing severe ankle pathologies, deformities, and failed prior interventions.

Clinical Evidence

No clinical data. Substantial equivalence supported by bench testing including static/dynamic four-point bending (ASTM F1264), static torsion (ASTM F1264), and axial pull-out (ASTM F543).

Technological Characteristics

Intramedullary fixation rod (21 CFR 888.3020). Components: fusion nails and bone screws. Mechanical testing per ASTM F1264 (bending/torsion) and ASTM F543 (screw pull-out). Biocompatible materials; sterilization and packaging validated.

Indications for Use

Indicated for adults (22+ years) requiring tibiotalar joint arthrodesis due to diabetic neuropathic ankle, severe deformity, osteoarthritis, tumor resection instability, Charcot deformity, talar avascular necrosis, failed joint replacement/fusion, distal tibial fracture/non-union, rheumatoid arthritis, or pseudoarthrosis.

Regulatory Classification

Identification

An intramedullary fixation rod is a device intended to be implanted that consists of a rod made of alloys such as cobalt-chromium-molybdenum and stainless steel. It is inserted into the medullary (bone marrow) canal of long bones for the fixation of fractures.

Predicate Devices

Reference Devices

Submission Summary (Full Text)

{1} FDA U.S. FOOD & DRUG ADMINISTRATION October 19, 2026 McGinley Orthopaedic Innovations % Hannah Irwin Director, Regulatory Affairs MCRA, LLC 803 7th St., NW Washington, District of Columbia 20001 Re: K261189 Trade/Device Name: Freedom Nail Ankle Fusion System Regulation Number: 21 CFR 888.3020 Regulation Name: Intramedullary fixation rod Regulatory Class: Class II Product Code: HSB Dated: September 15, 2026 Received: September 15, 2026 Dear Hannah Irwin: We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Before making any change significantly affecting the safety or effectiveness of the device, you must submit a new premarket notification in accordance with 21 CFR 807.81. Additional information about changes that U.S. Food & Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993 www.fda.gov {2} K261189 - Hannah Irwin Page 2 may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download). Your device is also subject to, among other requirements, the Quality Management System Regulation (QMSR) (21 CFR Part 820), which includes, but is not limited to, ISO 13485 clause 7.3 (Design controls), ISO 13485 clause 8.3 (Nonconforming product), ISO 13485 clause 8.5.2 (Corrective action), and ISO 13485 clause 8.5.3 (Preventative action). Please note that regardless of whether a change requires premarket review, the QMSR requires device manufacturers to review and approve changes to device design and production (ISO 13485 clause 7.3 and ISO 13485 clause 7.5) and document changes and approvals in the Medical Device File (ISO 13485 clause 4.2.3). Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products); good manufacturing practice requirements as set forth in the Quality Management System Regulation (QMSR) (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050. All medical devices, including Class I and unclassified devices and combination product device constituent parts are required to be in compliance with the final Unique Device Identification System rule ("UDI Rule"). The UDI Rule requires, among other things, that a device bear a unique device identifier (UDI) on its label and package (21 CFR 801.20(a)) unless an exception or alternative applies (21 CFR 801.20(b)) and that the dates on the device label be formatted in accordance with 21 CFR 801.18. The UDI Rule (21 CFR 830.300(a) and 830.320(b)) also requires that certain information be submitted to the Global Unique Device Identification Database (GUDID) (21 CFR Part 830 Subpart E). For additional information on these requirements, please see the UDI System webpage at https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/unique-device-identification-system-udi-system. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems. For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory- {3} K261189 - Hannah Irwin Page 3 assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100). Sincerely, JOSEPH P. RUSSELL -S for: Farzana Sharmin, PhD Assistant Director DHT6A: Division of Joint Arthroplasty Devices OHT6: Office of Orthopedic Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health Enclosure {4} # Indications for Use | Please type in the marketing application/submission number, if it is known. This textbox will be left blank for original applications/submissions. | | K261189 | ? | | --- | --- | --- | --- | | Please provide the device trade name(s). | | | ? | | Freedom Nail Ankle Fusion System | | | | | Please provide your Indications for Use below. | | | ? | | The Freedom Nail Ankle Fusion System is indicated for the following: Arthrodesis of the tibiotalar joint without limiting range of motion in the subtalar joint for any of the following indications: • Diabetic neuropathic ankle joint • Severe foot/ankle deformity • Osteoarthritis • Instability and skeletal defects after tumor resection • Neuro-arthropathic deformity or Charcot deformity • Avascular necrosis of the talus • Revision of a failed joint replacement or failed ankle fusion • Distal tibial fracture and non-unions • Rheumatoid arthritis and pseudoarthrosis | | | | | Please select the types of uses (select one or both, as applicable). | ☑ Prescription Use (21 CFR 801 Subpart D) ☐ Over-The-Counter Use (21 CFR 801 Subpart C) | ? | | | Please select the age group(s) for which the device(s) is to be used. | ☐ Neonates/Newborns (Birth to < 29 days old) ☐ Infants (29 days old to < 2 years old) ☐ Children (2 years old to < 12 years old) ☐ Adolescents (12 years old to < 22 years old) ☑ Adults (22 years old and greater) | ? | | {5} K261189 Page 1 of 3 # ***510(k) Summary*** | **Device Trade Name:** | Freedom Nail Ankle Fusion System | | --- | --- | | **Manufacturer:** | McGinley Orthopaedic Innovations 234 E 1^{st} St, Suite 242 Casper, WY 82601 | | **Contact:** | Mr. Adam Johnson Vice President of Engineering McGinley Orthopaedic Innovations 234 E 1^{st} St, Suite 242 Casper, WY 82601 Phone: (307) 315-6429 adam@mcginleyinnovations.com | | **Prepared by:** | MCRA, LLC 803 7^{th} Street, NW Washington, DC 20001 Office: (202) 552-5800 | | **Date Prepared:** | October 19, 2026 | | **Common Name:** | Intramedullary Nail | | **Classification:** | Intramedullary fixation rod (21 CFR 888.3020) | | **Class:** | II | | **Product Codes:** | HSB | | **Primary Predicate:** | Shotel Ankle Arthrodesis Nail System (K163627) | | **Additional Predicate Device:** | Diamond Orthopedic Bone Fixation Screws and Pins (K180932) | | **Reference Devices:** | Biomet Phoenix Ankle Nail and Ankle Arthrodesis Nail (K091976) Valor Ankle Fusion Nail System (K090857) | # **Indications For Use:** The Freedom Nail Ankle Fusion System is indicated for the following: Arthrodesis of the tibiotalar joint without limiting range of motion in the subtalar joint for any of the following indications: {6} K261189 Page 2 of 3 - Diabetic neuropathic ankle joint - Severe foot/ankle deformity - Osteoarthritis - Instability and skeletal defects after tumor resection - Neuro-arthropathic deformity or Charcot deformity - Avascular necrosis of the talus - Revision of a failed joint replacement or failed ankle fusion - Distal tibial fracture and non-unions - Rheumatoid arthritis and pseudoarthrosis **Device Description:** The Freedom Nail Ankle Fusion System is an ankle arthrodesis nail intended to be implanted in the talus and distal tibia region for a tibiotalar joint fusion. The nail construct allows for preservation of the tibiotalar joint. The Freedom Nail Ankle Fusion System is composed of fusion nails, bone screws, and a set of instruments. **Substantial Equivalence:** The Freedom Nail Ankle Fusion System is substantially equivalent to the primary predicate device listed above with respect to indications, design, function, and performance. **Preclinical Testing:** All necessary testing has been performed for the worst-case configuration of the Freedom Nail Ankle Fusion System to assure substantial equivalence to its predicates and to demonstrate the subject devices perform as intended. All testing was performed on test units representative of finished devices. The performance of the Freedom Nail Ankle Fusion System was characterized through the following mechanical tests: - Static Four-Point Bending Compliance (ASTM F1264) - Static Four-Point Bending (ASTM F1264) - Static Torsion (ASTM F1264) - Dynamic Four-Point Bending (ASTM F1264) for nails and screws - Axial Pull-Out (per ASTM F543) assessment of screws Additional non-clinical testing included biocompatibility, sterilization validation, and packaging validation. The results of the preclinical testing demonstrate that the Freedom Nail Ankle Fusion System is at least as safe and effective as the legally marketed predicate devices, with the same intended use and highly similar device design and any differences between devices do not raise different questions of safety and effectiveness. As such, the subject device is substantially equivalent to the primary predicate device. **Clinical Testing:** Clinical testing was not necessary to support equivalence. {7} K261189 Page 3 of 3 # **Conclusion:** The subject device and the predicate device share the same intended use and similar technological characteristics. Further, select components of the Freedom Nail Ankle Fusion System are identical to those included in the reference device. The results of the non-clinical data demonstrate substantial equivalence to the primary predicate device listed above.
Innolitics
Guidance Recalls

Panel 1

/
Ready

Predicate graph will load when search results are available.

Embedding visualization will load when search results are available.

PDF viewer will load when search results are available.

Loading panels...

Select an item from Submissions

Click any panel, subpart, regulation, product code, or device to see details here.

Section Matches

Results will appear here.

Product Code Matches

Results will appear here.

Special Control Matches

Results will appear here.

Loading collections...